WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Sophie Morgan suddenly quits ITV show Loose Women as she reveals plans for emigration
The 7 Chinese Cities That Win Hearts of Tourists for Holiday Travel
Chinese Courts Empowered to Better Support Family Education, Protect Minors
Slogan, Mascots, emblem of Asian Winter Games unveiled
Ravens sign WR Qadir Ismail, the son of former NFL receiver Qadry Ismail
Construction Begins on Intangible Cultural Heritage Museum in Xinjiang
Marriage Registrations Fall to Record Low in China
Various Activities Themed on Eye Caring Held at Schools Across China
Germany's foreign minister visits Kyiv as Ukraine battles to hold off a Russian offensive
Xander Schauffele gets validation and records with one memorable putt at PGA Championship
China's Ancient Symbols Light up Upcoming World University Games